StockNews.AI
ATOS
StockNews.AI
152 days

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

1. Atossa plans a conference call on March 25, 2025. 2. Discussion to focus on Q4 and full-year 2024 results. 3. Atossa develops (Z)-endoxifen for breast cancer treatment. 4. Company aims to enhance patient outcomes and shareholder value. 5. Webcast available on their investor relations webpage.

Earnings
+4.09%Current Return
VS
-0.43%S&P 500
$0.720503/20 09:50 AM EDTEvent Start
$0.7503/21 03:52 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

A conference call for quarterly results typically indicates transparency, which can attract investors. Historically, companies that show proactive communication often see positive price movements post-announcement.

How important is it?

The upcoming earnings call can influence investor perceptions and trading activities, contributing to short-term price changes. The focus on financial results means it is a key event for current and potential shareholders.

Why Short Term?

The planned call gives the market immediate insight into financial performance, with potential for swift investor response. Price movements are usually felt around earnings announcements.

Related Companies

ATOS
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time March 20, 2025 09:13 ET  | Source: Atossa Therapeutics, Inc. SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024. The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Atossa Therapeutics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at www.atossatherapeutics.com. About Atossa Therapeutics        Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company’s lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including metastatic, neoadjuvant, adjuvant, and prevention settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.  ContactMichael Parks, VP Investor and Public Relations 484-356-7105michael.parks@atossainc.com

Related News